Comparison
Goserelin vs. Teduglutid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
65807-02-5
197922-42-2
Molecular weight
1269.43 g/mol
3752.13 g/mol
Half-life
4.2 h
no data
Sequence
pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH2no data
Mechanism of action
Goserelin
As a GnRH agonist, goserelin binds to the GnRH receptors of the pituitary gland. Initial stimulation transiently raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous receptor occupancy, however, the receptors become desensitized and down-regulated, which reduces LH and FSH secretion and consequently the production of testosterone or estrogen. This mechanistic relationship is documented in the pharmacological literature.
Teduglutid
Teduglutide activates the GLP-2 receptor, promoting growth and regeneration of small-intestinal villi, increasing nutrient and fluid absorption and thereby reducing dependence on parenteral nutrition. The glycine substitution at position 2 makes it resistant to rapid breakdown by DPP-4.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
2
of which in humans
4
2
Effects recorded
3
2
Open conflicts
1
0
Documented adverse events
2
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Goserelin and Teduglutid?
- Goserelin is classified as "Research other", while Teduglutid is classified as "Research other". Goserelin: Goserelin is a synthetic decapeptide and an agonist of gonadotropin-releasing hormone (GnRH). The medical literature describes it as a hormonal agent that suppresses the release of sex hormones through sustained receptor stimulation. Regulatory-approved indications include prostate cancer, advanced breast cancer, endometriosis, and endometrial thinning, among others. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Goserelin or Teduglutid?
- The highest available evidence level is "Human RCT" for Goserelin and "Human RCT" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Goserelin and Teduglutid in Germany and the United States?
- Germany: Goserelin — Prescription, Teduglutid — Prescription. United States: Goserelin — Prescription, Teduglutid — Prescription. These are factual summaries with source and review date on the individual pages.